Scott Brantley

Title: Scott Brantley: Innovator in ADHD Treatment

Introduction

Scott Brantley is a notable inventor based in Apex, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of attention deficit/hyperactivity disorder (ADHD). His innovative work has led to the development of a unique medication that addresses various attention deficit disorders.

Latest Patents

Scott Brantley holds a patent for the "Mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD)." This invention relates to a modified-release composition of mazindol, which is utilized in treating attention deficit disorders, including ADHD, and related conditions such as excessive daytime sleepiness. The patent highlights the importance of this medication for children, adolescents, and adults suffering from these disorders.

Career Highlights

Brantley is associated with NLS Pharmaceutics AG, a company dedicated to developing innovative treatments for central nervous system disorders. His work at the company has been instrumental in advancing therapeutic options for patients with ADHD and related conditions.

Collaborations

Scott Brantley has collaborated with notable colleagues, including Alexander C. Zwyer and Lewis P. Amsel. These partnerships have contributed to the successful development and implementation of his innovative ideas in the pharmaceutical industry.

Conclusion

Scott Brantley's contributions to ADHD treatment through his patented invention demonstrate his commitment to improving the lives of those affected by attention deficit disorders. His work continues to influence the field of pharmaceuticals and offers hope for better management of these conditions.